Apellis Pharmaceuticals (APLS) PT Lowered to $38 at Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Join SI Premium – FREE
Mizuho analyst Graig Suvannavejh lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $38.00 (from $39.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Ramelius Resources (RMS:AU) (RMLRF) PT Raised to AUD6.65 at Canaccord
- Verizon (VZ) PT Lowered to $55 at TD Cowen as 'SPCX Overhang Prevails'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
